Summary of the Conference Call for Zhaoyan New Drug (March 31, 2023) Company Overview - **Company**: Zhaoyan New Drug - **Industry**: Biopharmaceuticals and Laboratory Services Key Financial Highlights - **Net Profit**: 2025 net profit attributable to shareholders is projected at 298 million yuan (+302.08%), primarily due to the increase in experimental monkey prices contributing 476 million yuan in fair value changes [2][4] - **Revenue**: Total revenue for 2025 is 1.658 billion yuan, with domestic customers contributing 1.204 billion yuan (72.65%) and international customers 453 million yuan (27.35%) [4] - **Gross Profit**: Gross profit for 2025 is 343 million yuan, with a gross margin of 20.71%, impacted by intensified market competition leading to price declines [4][5] - **Operating Cash Flow**: Operating cash flow for 2025 is 445 million yuan, up 31.17% year-on-year, providing a solid financial foundation for innovation and expansion [5] Order and Market Dynamics - **New Orders**: New signed orders for 2025 reached 2.6 billion yuan (+41.3%), with Q4 alone contributing 960 million yuan (+118.18%) [2][5] - **Order Backlog**: As of the end of 2025, the order backlog totals 2.6 billion yuan, reflecting an 18.18% year-on-year increase [5] - **Price Recovery**: By Q4 2025, over 50% of new orders' growth was attributed to price increases, with expectations for significant gross margin improvement starting Q4 2026 [2][6] Supply Chain and Capacity - **Experimental Monkey Supply**: The supply of experimental monkeys remains tight, with prices expected to rise further in Q1 2026. The company is ensuring supply through its own monkey farms and cautious evaluation of imports [2][8] - **Capacity Expansion**: The company has expanded its capacity with a new 20,000 square meter facility in Suzhou and plans for a large facility in Guangzhou expected to be operational by 2027 [3][7] Technological Advancements - **Technological Focus**: The company has been developing organoid technology for 5-6 years, focusing on liver and heart applications. AI is being utilized in pathology to enhance efficiency [3][18] - **Clinical Services**: Although currently a small revenue contributor, the clinical services segment has gained experience in gene therapy and traditional therapies, with plans to secure more orders in 2026 [16] Market Outlook - **2026 Projections**: The company anticipates continued strong order growth in 2026, with a high double-digit increase expected. However, revenue and profit improvements may lag due to the timing of order confirmations [2][13] - **Price Trends**: The pricing for large animal experiments has returned to pre-adjustment levels, while small animal and canine experiment prices are still recovering [6][11] Challenges and Risks - **Import Challenges**: The import of experimental monkeys faces challenges, including finding reliable suppliers and limited quarantine facilities in China [12][17] - **Market Volatility**: The company is cautious about the potential risks associated with imported monkeys and is focused on maintaining quality standards [10] Conclusion Zhaoyan New Drug is positioned for growth with strong order momentum and a focus on technological advancements. However, challenges in supply and market conditions may impact short-term financial performance. The company is strategically planning for capacity expansion and technological integration to enhance its competitive edge in the biopharmaceutical industry.

Summary of the Conference Call for Haijia Medical Company Overview - **Company**: Haijia Medical - **Industry**: Healthcare Services Key Points Financial Performance - In 2025, operating cash flow is expected to grow by 34.4% year-on-year to RMB 9.5 billion, driven by increased revenue from self-paid services and improved collection efficiency with accounts receivable down by 16.6% [2][3] - Inventory turnover efficiency improved by over 10% [2] - Depreciation and amortization is approximately RMB 310 million, indicating a strong cash return phase [2] - The company has a maximum capacity of 14,000 beds, sufficient to support five years of development with no new hospital construction plans in the short term [2][3] Capital Allocation and Shareholder Returns - The company plans to execute a RMB 300 million share buyback and intends to cancel the repurchased shares [2][9] - There is a focus on reducing interest-bearing debt and exploring quality domestic and international acquisitions [2][3] - Expected normalized free cash flow post the opening of Changshu Hospital in late 2026 is projected to reach RMB 800-900 million [2] Growth Areas - International medical and innovative business segments are emerging growth drivers, with Chongqing Hospital's international department generating over RMB 8 million in revenue in December 2025 [2][4] - The brain-computer interface business is expected to generate annual revenue of approximately RMB 250-260 million, with a dedicated division established in 2026 [2][11] M&A and Goodwill Impairment - The goodwill impairment related to Suzhou Yongding Hospital was due to high initial market valuations and changes in the macro environment, but the hospital's operations are currently stable [7] - Other acquired hospitals show no impairment pressure, indicating strong operational management capabilities [7] Response to Industry Changes - The company emphasizes a "patient-first" culture and has seen patient visits reach 4.6 million in 2025, with a five-year compound growth rate of 35% [5][6] - Continuous investment in talent and technology, with 108 national-level professionals and 907 senior professionals by 2025 [6] - The company is focusing on refined management practices to enhance operational efficiency [6] Market Outlook and Strategy - The company is optimistic about the long-term healthcare demand driven by aging demographics, despite short-term policy uncertainties [5][14] - Plans to leverage the long-term care insurance policy to tap into the growing demand for integrated medical and nursing services [8][16] AI Integration - AI is being integrated into management and service efficiency, with applications in supply chain and administrative management [13] - The company has developed an AI customer service system to enhance patient interaction and satisfaction [13] Future Projections - The company expects to achieve breakeven cash flow for the Texas Hospital by the end of 2026, with Wuxi Hospital anticipated to connect to medical insurance by March-April 2026 [9] - Long-term growth is expected for Chang'an Hospital, with multiple growth points identified in critical care and oncology [17] Valuation Perspective - The company's value is considered significantly undervalued, with approximately RMB 800 million in free cash flow and a focus on long-term cash flow stability [18] Additional Insights - The company maintains a cautious approach to overseas acquisitions, focusing on smaller projects initially while prioritizing domestic growth opportunities [16] - The operational efficiency and strategic management are seen as key competitive advantages in a changing healthcare landscape [16]

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 136.15 CNY per share [6][9]. Core Views - The company reported a revenue of 6.67 billion CNY and a net profit attributable to shareholders of 1.13 billion CNY for 2025, representing year-on-year growth of 14.91% and 19.35% respectively [1][2]. - The company is expected to achieve a revenue growth of 19%-22% in 2026 due to continuous order growth and improving operational conditions [2][3]. - The total order backlog reached 1.385 billion USD, a year-on-year increase of 31.65%, with significant growth in orders for chemical and biological macromolecule CDMO services [3]. - The company is actively expanding its production capacity, with plans to increase the total capacity for peptide solid-phase synthesis from 45,000L to 69,000L by the end of 2026 [3]. - The company has a rich pipeline of mid-to-late stage projects, with expectations for multiple commercialized projects in both small molecule CDMO and emerging business sectors in 2026 [4]. Financial Summary - The projected net profits for the company from 2026 to 2028 are 1.40 billion CNY, 1.74 billion CNY, and 2.21 billion CNY, reflecting year-on-year growth rates of 23.8%, 24.3%, and 27.0% respectively [5]. - The company’s earnings per share (EPS) for 2026 is estimated to be 3.89 CNY, with a price-to-earnings (PE) ratio of 35 times, leading to a target price of 136.15 CNY per share [9]. - The company’s revenue is expected to grow from 5.8 billion CNY in 2024 to 12.46 billion CNY in 2028, with a compound annual growth rate (CAGR) of 23.0% [10][11].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][4]. Core Views - The company is experiencing high-quality revenue and profit growth, entering an accelerated growth cycle due to multiple sectors' favorable conditions [4]. - In 2025, the company achieved a revenue of 6.67 billion yuan, a year-on-year increase of 14.91%, and a net profit attributable to shareholders of 1.13 billion yuan, up 19.35% year-on-year [4]. - The adjusted net profit for 2025 was 1.25 billion yuan, reflecting a significant increase of 56.09% year-on-year, with an adjusted net profit margin of 18.8%, up approximately 5.0 percentage points [4]. - The company’s order backlog reached 1.385 billion USD by the end of 2025, a year-on-year growth of 31.65%, indicating a strong demand outlook [4]. Financial Summary - The company’s revenue is projected to grow from 8.07 billion yuan in 2026 to 12.17 billion yuan in 2028, with year-on-year growth rates of 21.0% and 23.0% respectively [7]. - The net profit attributable to shareholders is expected to increase from 1.51 billion yuan in 2026 to 2.31 billion yuan in 2028, with year-on-year growth rates of 33.0% and 24.4% respectively [7]. - The company’s gross margin is projected to improve from 42.8% in 2026 to 44.6% in 2028, while the net profit margin is expected to rise from 18.7% to 19.0% over the same period [7]. - The earnings per share (EPS) is forecasted to grow from 4.18 yuan in 2026 to 6.41 yuan in 2028, with corresponding price-to-earnings (P/E) ratios decreasing from 24.1 to 15.7 [7]. Business Performance - The small molecule CDMO segment generated revenue of 4.735 billion yuan in 2025, a year-on-year increase of 3.59%, with a gross margin of 46.83% [5]. - The chemical macromolecule CDMO business saw rapid growth, achieving revenue of 1.028 billion yuan in 2025, up 123.72% year-on-year, with a significant increase in order backlog [5]. - The biopharmaceutical CDMO business also showed strong momentum, with revenue growth of 95.76% year-on-year and a substantial increase in order backlog [5]. - The company is expected to enter an accelerated growth phase in 2026, driven by the approval and market release of several blockbuster drugs [5].

Macro Commentary - China's manufacturing PMI rebounded significantly in March, partly due to the later and longer Spring Festival holiday in 2026, although it remains in a contraction state based on the three-month moving average. Both supply and demand have improved significantly, with inventory cycles and import/export orders showing recovery [2] - The non-manufacturing PMI slightly increased, indicating a return to expansion in the service sector, while the construction sector remains in contraction. The price indices for both manufacturing and services suggest that upstream input inflation may lead to a positive PPI in the coming months [2] - The overall resilience of the RMB is maintained, fluctuating around 6.9 against the USD despite a strong dollar backdrop [4] Company Analysis Sunny Optical Technology (2382 HK) - The company is expected to achieve a revenue and net profit growth of 21% and 85% year-on-year in the second half of 2025, reaching RMB 23.6 billion and RMB 3 billion respectively. The net profit aligns with previous positive forecasts and exceeds market consensus by 44% due to a one-time investment gain from GoerTek [5] - Management guidance for 2026 indicates revenue and net profit growth of no less than 7% each, driven by a 5-10% increase in smartphone revenue and a 60% increase in IoT revenue, offsetting weakness in XR business [5] Yongda Automobile (3669 HK) - The company anticipates a significant impairment in 2025, with revenue expected to decline by 15% to RMB 27.5 billion in the second half of 2025, leading to a historical low overall gross margin of 7.0%. A total impairment of approximately RMB 4.9 billion is expected, resulting in a net loss of RMB 1.7 billion in the second half of 2025 [5] - Management plans to close 15-20 stores in 2026, with most related asset impairments already accounted for in 2025, suggesting no major impairments in 2026 [6] Sanofi Pharmaceutical (1530 HK) - The company is projected to achieve a revenue of RMB 17.7 billion in 2025, a 94.3% year-on-year increase, primarily due to a RMB 9.4 billion licensing income from Pfizer. However, product sales are expected to decline by 10.3% to RMB 8 billion due to national procurement policies [7] - The company is expected to maintain high levels of R&D investment to accelerate pipeline progress, with significant clinical advancements anticipated from the collaboration with Pfizer [8] Kanglong Chemical (300759 CH) - The company reported a 14.8% year-on-year revenue growth to RMB 14.1 billion in 2025, with adjusted net profit increasing by 13.0% to RMB 1.82 billion, both exceeding previous forecasts [10] - Management expects a revenue growth of 12-18% in 2026, with currency fluctuations negatively impacting growth guidance by 3 percentage points [11] Zhongji Xuchuang (300308 CH) - The company reported a strong FY25 performance with a revenue growth of 60% to RMB 38.2 billion and a net profit increase of 109% to RMB 10.8 billion, aligning with market expectations [14] - The gross margin improved significantly from 34.7% in FY24 to 42.6% in FY25, driven by strong shipments of high-speed optical modules and an increase in the proportion of silicon photonics products [14] OmniVision Technologies (603501 CH) - The company achieved a revenue growth of 12.1% to RMB 28.9 billion in FY25, with a net profit increase of 21.7% to RMB 4 billion, although slightly below market expectations [15] - The gross margin improved from 29.4% in FY24 to 30.6% in FY25, primarily due to the optimization of CIS product structure and increased contributions from automotive CIS revenue [15]

Core Viewpoint - 康龙化成's stock rose over 7%, reaching 20.16 HKD, with a trading volume of 94.7765 million HKD, following the release of its 2025 fiscal year performance report [1] Financial Performance - For the fiscal year 2025, 康龙化成 reported revenue of 14.095 billion RMB, an increase of 14.8% year-on-year [1] - The net profit attributable to the parent company was 1.664 billion RMB, a decrease of 7.2% year-on-year [1] - In Q4 2025, the company achieved a quarterly revenue of 4.009 billion RMB, up 15.93% year-on-year, and a net profit of 523 million RMB, up 40.76% year-on-year [1] - The company's laboratory services generated revenue of 8.1589 billion RMB, reflecting a year-on-year growth of 15.8% [1] - The gross profit margin for the fiscal year 2025 was 44.7% [1] Future Outlook - 华泰证券 noted that 康龙化成's overall performance is accelerating positively, with a continuous increase in customer inquiries [1] - The new order amount for 2025 increased by over 14% year-on-year, showing further acceleration compared to the over 13% growth in the first three quarters of 2025 [1] - Based on new orders and business trends, the company expects revenue growth of 12%-18% year-on-year for 2026 [1] - The ongoing recovery in downstream industry demand, combined with the company's strong core laboratory service capabilities and the maturation of other business segments, supports a positive outlook for 康龙化成 in 2026 [1]

Core Viewpoint - Hai Jiaya Medical (06078.HK) reported a significant decline in revenue and net profit for the year ending December 31, 2025, primarily due to macroeconomic factors and local healthcare policy adjustments [4][5]. Financial Performance - The company achieved revenue of RMB 4.009 billion, a year-on-year decrease of 9.8% - Net profit fell sharply by 73.0% to RMB 162 million, largely due to a RMB 283 million impairment and provision related to Etern Group Ltd. - Despite profit pressures, operating cash flow reached a record high of RMB 950 million, up 34.4% year-on-year - The company's interest-bearing debt decreased by RMB 343 million, a decline of 12.3% [4][5]. Business Development - The core oncology business showed stability, with over 102,000 surgeries performed, and the proportion of high-level surgeries increased by 6.4 percentage points year-on-year - The international medical business made significant progress, with Chongqing Hai Jiaya Hospital providing services to patients from Southeast Asia and opening a two-story ward - The company plans to replicate its international medical business model in more suitable hospitals, expanding into areas such as early cancer screening and comprehensive treatment [6]. Network Expansion and Technology Integration - As of March 2026, the company managed or operated 17 comprehensive hospitals focused on oncology, with one additional tertiary hospital under construction - The company is actively exploring AI applications in medical scenarios, including AI-assisted personalized precision radiotherapy and imaging diagnosis - AI technology is also being utilized in supply chain and financial management to optimize inventory and enhance efficiency, along with the launch of an AI customer service system for patient engagement [7][8].

Group 1 - The revenue from the clinical trial technical services segment reached 3.267 billion yuan, an increase from 3.178 billion yuan in the same period last year [1] - The revenue from clinical trial-related services and laboratory services increased by 4.1% year-on-year, from 3.425 billion yuan to 3.566 billion yuan [1] Group 2 - The company, Tigermed, reported an operating revenue of 6.833 billion yuan for the year ending December 31, 2025, representing a year-on-year increase of 3.48% [2] - The net profit attributable to the listed company was 888 million yuan, showing a significant increase of 119.15% year-on-year [2] - Basic earnings per share were reported at 1.04 yuan, with a proposed cash dividend of 1.26 yuan for every 10 shares to all shareholders [2]

Core Viewpoint - Kanglong Chemical (300759.SZ) reported a revenue of 14.095 billion yuan for the year 2025, reflecting a year-on-year growth of 14.82% while the net profit attributable to shareholders decreased by 7.22% to 1.664 billion yuan [1] Financial Performance - The company achieved an operating income of 14.095 billion yuan, which is a 14.82% increase compared to the previous year [1] - The net profit attributable to shareholders was 1.664 billion yuan, showing a decline of 7.22% year-on-year [1] - The net profit excluding non-recurring gains and losses was 1.538 billion yuan, indicating a significant increase of 38.85% year-on-year [1] Dividend Distribution - The company proposed a dividend of 2 yuan per share to all shareholders [1]

Financial Data and Key Metrics Changes - For the year ended December 31, 2025, the company reported total revenue of approximately $54 million, an 18% decline from approximately $66 million in 2024, primarily due to lower contributions from healthcare operations [18] - Full year healthcare operations revenue was approximately $40 million compared to approximately $52 million in 2024, with Q4 revenues of approximately $9 million being relatively stable compared to $10 million in Q3 [19] - Consolidated gross margin for the full year was approximately 20%, down from approximately 26% in 2024, but with sequential improvement expected throughout 2026 [22] Business Line Data and Key Metrics Changes - The healthcare segment represented about 73% of total revenue in 2025, with a significant focus on higher margin 340B covered entities and medication fulfillment services [5][10] - The e-commerce segment saw revenue increase to approximately $15 million, up 6% year-over-year, driven by strong demand for satellite connectivity and IoT products [20] Market Data and Key Metrics Changes - The company reported a 94% increase in 340B contract revenue for Q4 2025 compared to Q3 2025, indicating strong growth in this area [9] - The expansion of healthcare operations from Florida to nationwide through a partnership with HealthWarehouse is expected to drive significant growth opportunities [10][16] Company Strategy and Development Direction - The company is focused on transitioning towards higher margin, recurring revenue streams, particularly in healthcare services, which is expected to improve margins and predictability over time [19] - The strategic refocusing and cost optimization initiatives have led to a reduction in operating expenses by approximately 25% to $20 million [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about early signs of margin improvement and a reduction in operating losses by the latter half of 2026 [8][26] - The company aims to leverage its partnership with HealthWarehouse to expand its healthcare offerings nationally and support multi-state contracted customers [26][27] Other Important Information - The company completed a reverse stock split to maintain its Nasdaq listing, which management believes was necessary despite investor negativity [3][4] - The company ended the year with nearly $14 million in cash and no meaningful debt, providing flexibility for operations and growth investments [23] Q&A Session All Questions and Answers Question: Was the reverse split necessary? - Management indicated that maintaining the Nasdaq listing was critical for growth and expansion plans, making the reverse split the most viable option at this time [27][28] Question: What are the current plans for the buyback? - Reinstating the buyback program is under consideration, with details to be announced when appropriate [28] Question: Can you comment on the status of ongoing lawsuits? - The company is working with counsel to resolve remaining legal matters while protecting shareholder interests, with options including proceeding to trial or reaching a settlement [29][30]